Patient perspectives on rheumatic and musculoskeletal diseases: insights from a large-scale survey.

Clin Rheumatol

Public Authority of Food and Nutrition, Sabah Al Salem, Kuwait.

Published: March 2025

Introduction/objectives: Rheumatic and musculoskeletal diseases (RMD) are prevalent among Arabic-speaking patients in the Middle East and North Africa (MENA), yet their perspectives remain underexplored. This study examines patient experiences and perspectives.

Method: A cross-sectional survey was developed using pilot testing with clinimetric sensibility assessment to ensure clarity and relevance, and the Open-Source Metric for Measuring Arabic Narratives (OSMAN) to assess readability. The Checklist for Reporting Internet E-Surveys (CHERRIES) was used to enhance the quality of the survey. The survey was distributed via social media to Arabic-speaking patients with self-reported RMDs. Collected data included demographics, disease characteristics, medication use, treatment satisfaction factors, perceived causes, and patient concerns.

Results: Of the 1050 responses received, 456 were complete and included in the analysis. Most respondents were female (81.4%) and between the ages of 25 and 44 (63.4%). The most frequently reported diseases were systemic lupus erythematosus, rheumatoid arthritis, and ankylosing spondylitis. Nearly all (97.1%) used medications within the previous three months, primarily hydroxychloroquine, glucocorticoids, and biologics. Key factors influencing treatment satisfaction were pain relief, laboratory result discussions, sleep quality, and mood improvement. Patients perceived immune system abnormalities (76.5%), psychological factors (54.8%), and genetics (41.7%) as primary disease causes. Main concerns included fear of disease complications, adverse drug reactions, and being a burden to others. Rheumatologists and internet search engines were the primary sources of information for patients. Most avoided alternative medicine, while 33.3% used it.

Conclusion: This survey is the first and largest in the MENA region, providing valuable insights into patient perspectives on RMD. It highlights the need for holistic management, enhanced education, and supportive services to improve quality of life. Key Points • The most commonly perceived causes of rheumatic and musculoskeletal diseases among patients with RMD were immune system abnormalities, psychological factors, genetic/hereditary influences, and envy. • Patients' top concerns included fear of future complications, adverse drug reactions, becoming a burden to others, physical disability, and issues related to marriage and childbirth. • Key factors influencing treatment satisfaction included pain relief, discussions of laboratory results, sleep quality, and mood improvement. • Approximately one-third of patients had consulted practitioners of complementary and alternative medicine.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-025-07388-xDOI Listing

Publication Analysis

Top Keywords

rheumatic musculoskeletal
12
musculoskeletal diseases
12
treatment satisfaction
12
patient perspectives
8
arabic-speaking patients
8
key factors
8
factors influencing
8
influencing treatment
8
pain relief
8
sleep quality
8

Similar Publications

Musculoskeletal diseases are the leading cause of disability-adjusted life years. Mitochondria, often referred to as the "powerhouses" of cells, are believed to play a role in regulating cellular metabolism and differentiation, potentially influencing the occurrence and progression of musculoskeletal diseases. However, the exact causal relationships remain to be defined.

View Article and Find Full Text PDF

Objectives: To compare the risk of serious infection across time cohorts in patients with inflammatory arthritis (IA) initiating their first biologic/targeted synthetic DMARD (b/tsDMARD), to that of the general population. Secondarily, to compare the development in infection risk during treatment across diagnoses and examine risk dynamics during the course of b/tsDMARD treatment.

Methods: Patients with IA starting their first b/tsDMARD were included from the prospective NOR-DMARD study.

View Article and Find Full Text PDF

Background: Rheumatic and musculoskeletal diseases, which are prevalent in nearly 25-30% of the Indian population, pose a significant burden on public health. However, the field is often overlooked in undergraduate medical curricula, leading to a shortage of adequately trained healthcare professionals to address these conditions, especially at the primary health care level. Enhancing rheumatology training for undergraduates in India is imperative.

View Article and Find Full Text PDF

Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.

Lancet Rheumatol

March 2025

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address:

Aberrant B-cell function, which could arise from various underlying causes, is central to the pathogenesis of diverse autoimmune rheumatic diseases. B cells remain the only cell type to be specifically therapeutically targeted through depletion and have the only therapy with a routinely available flow cytometric biomarker of treatment. Since first use and subsequent licensing for rheumatoid arthritis, rituximab has had a transformative impact on patients globally and across the rheumatic diseases.

View Article and Find Full Text PDF

Remission in gout is possible: 5-year follow-up in the NOR-Gout study.

Semin Arthritis Rheum

February 2025

Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; Faculty of Medicine, University of Oslo, Oslo, Norway.

Objective: To compare the performance of remission definitions for gout in an observational treat-to-target patient cohort with 5 years of follow-up.

Methods: Inclusion criteria were crystal proven gout with increased serum urate levels and a flare. Remission was determined according to the 2016 preliminary gout remission definition, a modified preliminary definition with more lenient thresholds for the individual variables pain due to gout and patient global assessment of gout disease activity, and the simplified definition without patient reported outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!